Following the discovery of HIV as a causative agent of AIDS, the expectation was to rapidly
develop a vaccine; but thirty years later, we still do not have a licensed vaccine. Progress …

The management of chronic conditions often requires patients to take daily medication for an
extended duration. However, the need for daily dosing can lead to nonadherence to the …

Advances in antiretroviral therapy (ART) have made it possible for persons with human
immunodeficiency virus (HIV) to live a near expected life span, without progressing to AIDS …

In light of the increasing global burden of new HIV infections, growing financial
requirements, and shifting funding landscape, the global health community must accelerate …

Before initiation of antiretroviral therapy (ART), HIV-specific CD8+ T cells are dysfunctional
and short lived. To better understand the relationship between the HIV reservoir in CD4+ T …

Background The objective of this study was to assess the durability of response of
dolutegravir (DTG) as an antiretroviral core agent by comparing its efficacy and safety with …

The widespread use of combination antiretroviral therapies (cART) has converted the
prognosis of HIV infection from a rapidly progressive and ultimately fatal disease to a chronic …

Objectives: Identify the mechanism of action of FDA-approved HIV medications. Describe the
adverse effects of HIV ART medications. Summarize the appropriate monitoring steps of …

In the last decade, over a dozen potent broadly neutralizing antibodies (bnAbs) to several
HIV envelope protein epitopes have been identified, and their in vitro neutralization profiles …

In preclinical and phase I and II clinical studies, 2′-deoxy-2′-β-fluoro-4′-azidocytidine
(FNC) displays a potent and long-lasting inhibition of HIV-1 infection. To investigate its …